74 results about "Obese Mice" patented technology

The present invention provides an antiobesity composition comprising extract of Melissa as an active ingredient, use of Melissa extract, and a method for suppressing obesity using the composition. Also, the present invention provides an antiobesity composition comprising extract of Melissa and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract and Mori Folium extract, and a method for suppressing obesity using the composition. Further, the present invention provides an antiobesity composition comprising extract of Melissa, extract of Artemisia and extract of Mori Folium as active ingredients, use of a mixture of Melissa extract, Artemisia extract and Mori Folium extract, and a method for suppressing obesity using the composition. When the present compositions are administrated into genetically obese mice or high fat diet-induced obese mice, the present compositions reduced body weight, body fat and gonadal fat, and reduce blood cholesterol level and obesity-related blood glucose level. Also, the present compositions suppress hypertrophy of adipocytes, and inhibit the accumulation of lipid in the liver by reducing the size and number of lipid vacuoles. Furthermore, in human clinial trial the present compositions show that body weight, PIBW, body fat, especially visceral fat, apolipoprotin B concentration, ratio of total cholesterol/HDL cholesterol and ratio of LDL cholesterol/HDL cholesterol are significantly decreased, and atherogenic index is improved and muscle mass is increased. Thus, the present compositions can be usefully applied as antiobesity composition for reduction of body weight and suppression of abdominal fat, particularly, visceral fat.

An obese mouse model was developed by overexpressing the mitochondrial protein prohibitin (PHB) in white adipose tissue (WAT) specific manner driven by adipocyte protein 2 (aP2) promoter. These mice begin to develop obesity as a result of mitochondrial remodeling (upregulation of mitochondrial biogenesis and function) in WAT.

The invention discloses a Lycium ruthenicum anthocyanin and a preparation method thereof. The preparation method comprises the following steps: preparing a Lycium ruthenicum anthocyanin powder; extracting the Lycium ruthenicum anthocyanin; and purifying and freeze-drying the Lycium ruthenicum anthocyanin. The Lycium ruthenicum anthocyanin prepared in the invention has good ability to remove DPPH free radicals and hydroxyl free radicals, and has influences on fat accumulation, lipid metabolism and insulin tolerance of obese mice.

The invention discloses a diethylstilbestrol compound and application thereof in preparation of a drug for treating osteoporosis and/or hyperlipemia. The structural formula of the diethylstilbestrol compound is shown in the specification. The data of a cellular level pharmacodynamic test show that cajanstilbene H (R is H, and X is Cl) can promote multiplication and osteogenic differentiation of bone marrow mesenchymal stem cells (BMSCs) of an SD rat. After an ob/ob obese mice orally takes the cajanstilbene H (20 mg/kg/d) continuously for 21 days, the results are as follows: (1) no obvious effect on weight is generated; (2) the bone density of the mice is obviously increased; serum alkaline phosphatase (ALP) and tartrate resistant acid phosphatase (TRACP) level are obviously reduced; and the serum calcium concentration is improved; and (3) levels of total cholesterol (TC), triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C) in the serum of the mice are obviously reduced. The results show that the cajanstilbene H has positive significance in treatment of the osteoporosis caused by obesity and high blood sugar, and has a clear curative effect on the aspect of improvement of lipid metabolism of the obese mice. The cajanstilbene H has a clear treatment effect on the osteoporosis caused by obesity and high blood sugar and simultaneously can improve lipid metabolism; and metabasis of hyperlipemia to diabetes mellitus to chronic complication of diabetes mellitus to osteoporosis can be avoided to a certain extent.

The invention designs a novel lipid-lowering polypeptide P48. The novel lipid-lowering polypeptide P48 is prolonged in a half-life period, plays the role of a GLP-1 receptor agonist and also plays therole of a GLP-1 analogue to adjust the fat content of an individual. The P48 peptide can be used for inhibiting feed intake of a non-alcoholic fatty liver model mouse induced by high-fat diet, remarkably reduce the weight of an obese mouse, lower the blood fat level of the obese mouse, maintain the normal form of the liver, inhibit liver cell injury, reduce accumulation of lipid in the liver andvacuolar deformation of cells, increase the level of adiponectin leptin in blood, and give a play to the blood glucose reducing and blood fat regulating effects of the adiponectin leptin; meanwhile, the P48 peptide obviously improves insulin tolerance and sugar tolerance. The novel lipid-lowering polypeptide P48 of the invention has potential pharmaceutical application in preparation of drugs fortreating and preventing obesity or complications thereof, namely non-alcoholic fatty liver diseases.

The invention relates to the field of medicament preparation, and particularly relates to applications of a Periostin gene and a Periostin antibody in preparation of medicaments. The Periostin gene expression is closely relevant to the occurrence and development of NAFLD (Nonalcoholic Fatty Liver Disease) and hyperlipidemia through remarkable expression increase of the Periostin gene in the liver of a high-fat diet-induced obesity mouse, the significant expression rise of Periostin in a patient with fatty liver, and obvious positive correlation between the Periostin and liver TG (Triglyceride) content as well as serum TG content, and the Periostin gene and the Periostin antibody can be used for preparing and screening a NAFLD reagent and a hyperlipidemia reagent. The Periostin antibody can be used for neutralizing Periostin in the obese mouse body, obviously reducing the liver/weight ratio, and the TG content of the liver and serum, therefore, the Periostin antibody achieves the effects of obviously improving the development of the NAFLD and reducing the TG content in serum.

The invention discloses an application of lactobacillus casei and ginkgo leaf extract in preparing medicines used for controlling hyperlipidemia. With a synergetic effect of lactobacillus casei and ginkgo leaf extract, obese mice body mass, TC, TG and MDA are substantially reduced. Degradation rates of TC and TG are respectively improved by 24.48% and 20.93%; mice weight is reduced by 13.22% than a high-fat group; and MDA content is reduced by 5.98%. In mice serum, HDL-C is substantially increased, wherein an increasing rate reaches 167.85%. GSH-PX in mice body is increased by 13.14%. Activities of enzymes such as CAT and SOD are respectively reduced by 49.02% and 3.13%. With the synergetic effect of lactobacillus casei and ginkgo leaf extract, functions of blood fat reducing, cholesterol metabolism promoting, and weight controlling are provided. Therefore, lactobacillus casei and ginkgo leaf extract can be used in preventing and treating hyperlipidemia.

The invention discloses a human secretory FNDC5 protein as well as a preparation method and application thereof, and relates to the technical field of gene engineering. The human secretory FNDC5 protein does not contain a transmembrane structural domain and can be directly secreted and released into blood. The human secretory FNDC5 protein can be used for preparing medicines for treating atherosclerosis, medicines for promoting bone formation and medicines for treating aplastic anemia, and can be used for preparing endothelial cell proliferation medicines. After fasting injection is conductedon a high-fat fed obese mouse model, the human secretory FNDC5 protein can effectively reduce the weight of an obese mouse, which shows that the protein can obviously improve body fat metabolism of anobese patient and obviously reduce the levels of plasma cholesterol, free fatty acid and triglyceride, and shows that the protein can obviously improve lipid metabolism disorder of the obese patient.

The invention discloses weight-losing application of a apios americana flower ethanol extract and provides novel resources for developing natural weight-losing products in the fields of medicine, foodsciences and the like. According to the weight-losing application disclosed by the invention, proved by an experiment of inducing obese mice by high fat diet, the apios americana flower ethanol extract has the advantages that body weight of the obese mice can be remarkably reduced, the contents of triglyceride and total cholesterol in serum and liver are reduced, and the effects are comprehensiveand obvious. Therefore, the apios americana flower ethanol extract disclosed by the invention is applied to prepare weight-losing food or drugs so as to treat and prevent obesity and associated chronic diseases thereof.

The invention discloses an application of a chinaroot greenbrier alcohol extract to preparation of a weight and fat reducing medicine. The chinaroot greenbrier alcohol extract can suppress cholesterol synthesis, promote fat oxygenolysis, decrease the lipid content of serum and livers, finally suppress fat deposition in an abdominal cavity and reduce increase of the body weight of mice by adjusting expression of lipid metabolism related genes and protein in high fat diet-induced obese mouse livers and fat tissues and adjusting activity of lipolysis related enzyme in the livers. The weight and fat reducing medicine is clear in target, small in side effect and high in clinical effective rate.

The invention belongs to the field of biotechnology and discloses application of an IL-27 receptor activator to preparation of products for treating obesity and complications thereof. IL-27 receptor deficient mice are more prone to obesity than wild type mice, and IL-27 is effective in delaying of an obesity occurrence process. By IL-27 application, body weight growth of obese mice can be effectively inhibited, microphage infiltration in adipose tissues of the obese mice can be effectively relieved, and insulin resistance conditions of the obese mice can be effectively improved.

The invention relates to the technical field of medicines, and discloses an application of triptonide. The invention finds that the Chinese herbal medicine monomer triptonide can significantly reducethe formation of thoracic aortic atherosclerotic plaques, accumulation of tricuspid valve fat and formation of collagenous fibers of high-fat diet mice, and significantly reduce the weight and fat accumulation of the high-fat diet mice. In addition, the triptonide can also obviously reduce the content of low-density lipoprotein and cholesterol in the blood of the high-fat diet obese mouse. Therefore, the triptonide has the treatment effect on atherosclerosis, so that the triptonide can be applied to the preparation of related medicines, the atherosclerosis is a main reason for coronary heart disease, cerebral infarction and peripheral vascular disease, and the triptonide can also be applied to the preparation of the related medicines for coronary heart disease, cerebral infarction and peripheral vascular disease.

The invention relates to medical application of long-chain non-coding RNA (LncRNA-266), in particular to application of LncRNA-266 in preparation of a drug for inducing brown adipose cell differentiation, which can promote body energy consumption and resist obesity. Obese mice are treated by the LncRNA-266, and a result shows that the LncRNA-266 can promote differentiation of beige fat cells of the obese mice to brown fat cells and consume body energy, so that weight gain is inhibited. It is further found that the LncRNA-266 can reduce the blood glucose level of obese mice and improve the insulin sensitivity.

The invention belongs to the field of biomedicine, and particularly relates to application of macrophages expressing IL-4 protein in obesity treatment and blood sugar regulation. The application of the macrophage and a composition comprising the macrophage is as follows: (1) application in preparation of products for treating obesity; (2) application in preparation of products for reducing blood sugar; and (3) application in preparation of products for treating diabetes caused by obesity. The macrophage is a macrophage expressing an IL-4 (Interleukin-4) protein. When intraperitoneal injection is carried out on obese mice by using the prepared macrophage expressing the IL-4 protein, namely a lentivirus pCDH-IL-4 infected RAW264.7 cell, the weight of the mice can be effectively reduced, and the blood glucose level of the mice after glucose uptake is reduced. Therefore, it is proved that macrophages expressing the IL-4 protein can treat obesity and reduce blood sugar, new therapeutic drugs and methods are provided for clinically treating obesity and other diseases such as diabetes caused by obesity, and important application value is achieved for treating the obesity and other diseases such as the diabetes caused by obesity.